[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
OBJECTIVE
To compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).


METHODS
Early-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.


RESULTS
Ninety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.


CONCLUSIONS
NCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Weiping
W
Liu
Xiaopei
X
Wang
Chen
C
Zhang
Yan
Y
Xie
Ningjing
N
Lin
Meifeng
M
Tu
Lingyan
L
Ping
Zhitao
Z
Ying
Lijuan
L
Deng
Huiying
H
Huang
Meng
M
Wu
Yingli
Y
Sun
Tingting
T
Du
Xin
X
Leng
Ning
N
Ding
Wen
W
Zheng
Yuqin
Y
Song
Jun
J
Zhu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis*; D008875:Middle Aged; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone